吉非替尼治疗化疗失败的晚期消化道肿瘤15例分析  

The Analysis of Gefitinib in the Treatment of 15 Cases with Advanced Gastrointestinal Tumors Failed to Chemotherapy

作　　者：曹风军[1] 俞远东[1] 雷金华[1] 邰云燕[1] 邓守恒[1] 陈萍[1] 

机构地区：[1]郧阳医学院附属人民医院肿瘤中心,442000

出　　处：《实用癌症杂志》2010年第6期616-617,626,共3页The Practical Journal of Cancer

摘　　要：目的探讨吉非替尼单药治疗化疗失败的晚期消化道肿瘤的疗效及不良反应。方法 15例经病理学检查确诊的晚期消化道肿瘤患者,经多周期化疗后病情进展后口服吉非替尼250mg/d,直至病情进展或不能耐受不良反应停药。按WHO标准评价疗效及不良反应。结果 15例中,CR1例,PR2例,SD5例,疾病控制率为53.3%(8/15),全组中位疾病进展时间为90天,中位生存时间为151天,主要不良反应为胃肠道反应和皮疹。结论吉非替尼为化疗失败的晚期消化道肿瘤患者提供了1条新的治疗途径,不良反应轻,患者耐受性较好,临床疗效和机理有待进一步研究。Objective To investigate the effects and adverse reactions of gefitinib therapy for chemotherapy failed advanced gastrointestinal cancers.Methods 15 patients with pathologically confirmed advanced gastrointestinal cancer and with progression diseases after multi-cycle chemotherapy,were treated by gefitinib 250 mg/d.Treatment was stopped until disease progression or with intolerable side effects.Results Of the 15 cases,there were 1 complete response,2 partial response,and 5 stable disease,with a total response rate of 53.3%.The median time to progression was 90 days,and the median survival time was 151 days.The main side effects were nausea and skin rash.Conclusion Gefitinib provide a new therapeutic approach for chemotherapy failed patients with advanced gastrointestinal tumors.The adverse reactions were mild and well tolerated.

关 键 词：吉非替尼 晚期消化道肿瘤 

分 类 号：R735[医药卫生—肿瘤]